Financial Results Archives

Excellent growth and progress in H1 2026

What a start to 2026! We announced excellent financial results today. Total sales grew by 23.5% at constant exchange rates,

We have delivered a strong start to 2026, reporting total sales growth of 22.6% at constant exchange rates in the

FY 2025 was a year of strong execution and robust performance across all therapeutic areas, driving significant topline growth and

We are proud to announce our robust performance across all therapeutic areas in the first nine months of 2025, underscoring

The first six months of 2025 have been exceptional for Ipsen. We’ve delivered strong growth across all three of our

Our performance in 2024 confirmed that our strategic initiatives are paying off, with significant advancements and robust financial growth across

The first six months of 2024 saw excellent sales growth of 9.5% at CER, and a core operating margin of